小程序掃碼下單
本網(wǎng)站銷(xiāo)售的所有產(chǎn)品僅用于工業(yè)應(yīng)用或者科學(xué)研究等非醫(yī)療目的，不可用于人類(lèi)或動(dòng)物的臨床診斷或者治療，非藥用，非食用。
Reslizumab
英文名：
Cas號(hào)：241473-69-8
Cas號(hào)：241473-69-8
檢測(cè)信息查詢(xún)
| 貨號(hào) | 規(guī)格 | 貨期 | 庫(kù)存 | 價(jià)格 | 促銷(xiāo)價(jià) | 訂購(gòu) |
| 1308132498-1mg | 0 | ￥25000 |
| 別 名 | |
| Cas號(hào) | 241473-69-8 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產(chǎn)品參數(shù) | Description
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2]. IC50 & Target IC50: 91.1pM (IL-5-dependent cell proliferation)[1] Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298. [2]. Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4. |
| 性狀 | Reslizumab (Sch 55700) 是靶向人白介素 5 (IL-5) 的人源化單克隆抗體，用于治療嗜酸性粒細(xì)胞性哮喘。Reslizumab 可有效阻斷 IL-5 的功能。Reslizumab 抑制 IL-5 依賴(lài)性細(xì)胞增殖，IC50 值約為 91.1pM。Reslizumab 對(duì)人 IL-5 具有高結(jié)合親和力，在 Biacore 表面等離振子共振和動(dòng)力學(xué)排斥分析中，KD 值分別為 109 pM 和 4.3 pM |
| 貯存 |
- 雷莫蘆單抗 947687-13-0
- Human IgG1 Control
- Abatacept 332348-12-6
- Obinutuzumab
- Reslizumab 241473-69-8
- 那他珠單抗 189261-10-7
- BENRALIZUMAB 1044511-01-4
- Dupilumab 1190264-60-8
- 重組人FGF-ACIDIC
滬公網(wǎng)安備 31012002003054號(hào)